Last $0.81 USD
Change Today +0.01 / 1.25%
Volume 19.9K
RGDX On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 4:30 PM 08/27/14 All times are local (Market data is delayed by at least 15 minutes).

Financial Statements for response genetics inc (RGDX)

This company's debt to total capital ratio, at 18.34%, is in-line with the Life Sciences Tools and Services industry's norm. Additionally, there are enough liquid assets to satisfy current obligations. Cash Collection is among the best in the industry. At the end of 2013, its uncollected receivables totaled $6.2M USD, which, at the current sales rate provides a Days Receivables Outstanding of 106.90. However, the company has been extending its suppliers more credit than in years past.
Currency in
Millions of US Dollars
As of:Dec 31
2010
Restated
Dec 31
2011
Restated
Dec 31
2012
Dec 31
2013
4 Year
Trend
Assets    
Cash and Equivalents4.11.79.08.1
TOTAL CASH AND SHORT TERM INVESTMENTS4.11.79.08.1
Accounts Receivable4.74.05.46.2
Other Receivables--0.0----
TOTAL RECEIVABLES4.74.05.46.2
Prepaid Expenses0.91.00.61.0
TOTAL CURRENT ASSETS9.86.715.015.4
Gross Property Plant and Equipment3.33.94.35.7
Accumulated Depreciation-2.6-2.8-3.3-3.8
NET PROPERTY PLANT AND EQUIPMENT0.71.01.01.9
Other Intangibles0.10.10.60.8
TOTAL ASSETS10.67.916.618.1
    
LIABILITIES & EQUITY    
Accounts Payable1.21.51.21.7
Accrued Expenses3.23.32.43.8
Short-Term Borrowings--1.01.0--
Current Portion of Long-Term Debt/Capital Lease--0.10.20.2
Current Portion of Capital Lease Obligations--0.10.20.2
Unearned Revenue, Current1.5--0.5--
TOTAL CURRENT LIABILITIES5.95.95.35.7
Long-Term Debt------1.0
Capital Leases--0.20.10.1
Unearned Revenue, Non-Current0.1------
Other Non-Current Liabilities7.97.911.85.5
TOTAL LIABILITIES13.914.017.112.3
Common Stock0.10.10.20.3
Additional Paid in Capital40.643.556.871.0
Retained Earnings-43.8-49.5-57.3-65.3
Comprehensive Income and Other-0.2-0.3-0.3-0.3
TOTAL COMMON EQUITY-3.3-6.1-0.55.8
TOTAL EQUITY-3.3-6.1-0.55.8
TOTAL LIABILITIES AND EQUITY10.67.916.618.1
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGDX:US $0.81 USD +0.01

RGDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cancer Genetics Inc $9.41 USD +0.66
NeoGenomics Inc $5.45 USD +0.03
Rosetta Genomics Ltd $3.71 USD 0.00
Signal Genetics Inc $4.73 USD +0.22
Veracyte Inc $12.87 USD +0.10
View Industry Companies
 

Industry Analysis

RGDX

Industry Average

Valuation RGDX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.8x
Price/Book 6.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RESPONSE GENETICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.